{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:20:15Z","timestamp":1789237215765,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118272","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T03:22:42Z","timestamp":1750044162000},"page":"118272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Lansoprazole identified as a prophylactic agent for oxaliplatin-induced peripheral neuropathy using integrated in silico, in vitro, and in vivo analyses"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2118-5280","authenticated-orcid":false,"given":"Akihide","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-9571","authenticated-orcid":false,"given":"Kenji","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5207-9898","authenticated-orcid":false,"given":"Eri","family":"Wakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118272_bib1","article-title":"Cisplatin and oxaliplatin: our current understanding of their actions","volume":"18","author":"Riddell","year":"2018","journal-title":"Met. Ions Life Sci."},{"key":"10.1016\/j.biopha.2025.118272_bib2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/jjco\/hym069","article-title":"Phase II study of oxaliplatin in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines","volume":"37","author":"Boku","year":"2007","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118272_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pain.2009.03.024","article-title":"Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study","volume":"144","author":"Attal","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2025.118272_bib4","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1016\/j.ejca.2007.07.030","article-title":"Pain in oxaliplatin-induced neuropathy\u2014sensitisation in the peripheral and central nociceptive system","volume":"43","author":"Binder","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118272_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2407-5-116","article-title":"Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer","volume":"5","author":"Leonard","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2025.118272_bib6","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","article-title":"Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance)","volume":"33","author":"Pachman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118272_bib7","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1305321110","article-title":"Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2","volume":"110","author":"Sprowl","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2025.118272_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1023\/B:NEON.0000021787.70029.ce","article-title":"Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y","volume":"67","author":"Donzelli","year":"2004","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.biopha.2025.118272_bib9","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1172\/JCI136796","article-title":"Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice","volume":"130","author":"Huang","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2025.118272_bib10","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1158\/2767-9764.CRC-22-0172","article-title":"Targeting OCT2 with duloxetine to prevent oxaliplatin-induced peripheral neurotoxicity","volume":"2","author":"Nepal","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.biopha.2025.118272_bib11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118272_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204648","article-title":"An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs","volume":"13","author":"Hosomi","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118272_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41573-023-00832-0","article-title":"Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR","volume":"23","author":"Tropsha","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118272_bib14","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1038\/s41598-024-79377-0","article-title":"Identification of dequalinium as a potent inhibitor of human organic cation transporter 2 by machine learning based QSAR model","volume":"15","author":"Yamane","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118272_bib15","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2025.118272_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56900-2","article-title":"Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein","volume":"9","author":"Ikemura","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118272_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jphs.2019.10.005","article-title":"Improvement of peripheral vascular impairment by a phosphodiesterase type 5 inhibitor tadalafil prevents oxaliplatin-induced peripheral neuropathy in mice","volume":"141","author":"Ogihara","year":"2019","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2025.118272_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.biopha.2025.118272_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2990.2002.00366.x","article-title":"Lysosomal storage results in impaired survival but normal neurite outgrowth in dorsal root ganglion neurones from a mouse model of Sandhoff disease","volume":"28","author":"Sango","year":"2002","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.biopha.2025.118272_bib20","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.21873\/anticanres.16764","article-title":"Proton pump inhibitors ameliorate oxaliplatin-induced peripheral neuropathy: retrospective analysis of two real-world clinical databases","volume":"43","author":"Kobayashi","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.biopha.2025.118272_bib21","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.3390\/ijms22126439","article-title":"In vitro inhibition of renal OCT2 and MATE1 secretion by antiemetic drugs","volume":"22","author":"George","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118272_bib22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3389\/fphar.2017.00911","article-title":"Drug repositioning of proton pump inhibitors for enhanced efficacy and safety of cancer chemotherapy","volume":"8","author":"Ikemura","year":"2017","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2025.118272_bib23","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.neuro.2006.04.010","article-title":"Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding","volume":"27","author":"Ta","year":"2006","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.biopha.2025.118272_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/jnc.14607","article-title":"Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy","volume":"148","author":"Fujita","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2025.118272_bib25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/jpet.111.181297","article-title":"Oxaliplatin transport mediated by organic cation\/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons","volume":"338","author":"Jong","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.118272_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/dmd.105.006932","article-title":"Tissue distribution and ontogeny of organic cation transporters in mice","volume":"34","author":"Alnouti","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2025.118272_bib27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.bcp.2007.03.004","article-title":"Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity","volume":"74","author":"Yokoo","year":"2007","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.biopha.2025.118272_bib28","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.3390\/ijms23168859","article-title":"Omeprazole suppresses oxaliplatin-induced peripheral neuropathy in a rodent model and clinical database","volume":"23","author":"Mine","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118272_bib29","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.21873\/anticanres.15737","article-title":"Proton pump inhibitors ameliorate capecitabine-induced hand-foot syndrome in patients with breast cancer: a retrospective study","volume":"42","author":"Takemura","year":"2022","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2025.118272_bib30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00280-017-3426-2","article-title":"Repositioning of proton pump inhibitors in cancer therapy","volume":"80","author":"Lu","year":"2017","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.biopha.2025.118272_bib31","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1007\/s12035-018-0920-4","article-title":"Rosmarinic acid mitigates mitochondrial dysfunction and spinal glial activation in oxaliplatin-induced peripheral neuropathy","volume":"55","author":"Areti","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2025.118272_bib32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.taap.2017.03.009","article-title":"Carvedilol prevents functional deficits in peripheral nerve mitochondria of rats with oxaliplatin-evoked painful peripheral neuropathy","volume":"322","author":"Areti","year":"2017","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.biopha.2025.118272_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrn2533","article-title":"Pathological and protective roles of glia in chronic pain","volume":"10","author":"Milligan","year":"2009","journal-title":"Nat. Rev. Neurosci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:48:11Z","timestamp":1754653691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225004664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"alternative-id":["S0753332225004664"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118272","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lansoprazole identified as a prophylactic agent for oxaliplatin-induced peripheral neuropathy using integrated in silico, in vitro, and in vivo analyses","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118272"}}